Year-over-year, this metric declined by 100.0%, from $1.15B to $0.00. Over 2 years (FY 2023 to FY 2025), Goodwill impairment shows a downward trend with a -33.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase signals potential overpayment for past acquisitions or a deterioration in the long-term outlook of acquired business units.
The non-cash charge recognized when the carrying amount of goodwill exceeds its implied fair value. This reflects a down...
Common across companies with active M&A strategies; peers often report this periodically during annual impairment testing.
goodwill_impairment| Q3 '21 | Q4 '21 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $2.25B | $0.00 | $0.00 | $0.00 | $2.62B | $0.00 | $64.00M | $0.00 | $0.00 | $1.15B | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | — | — | -100.0% | — | — | — | -100.0% | — | -100.0% | — | — | -100.0% | — | — | — |
| YoY Change | — | — | — | — | — | -100.0% | — | — | — | — | -100.0% | — | -100.0% | — | — | -100.0% |
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Food Ingredients | — | — | — | — | $1.15B | — | — | — |
| Health & Biosciences | — | — | — | — | $0.00 | — | — | $0.00 |
| Nourish | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Pharma Solutions | $16.00M | $16.00M | $16.00M | $16.00M | $0.00 | $0.00 | $0.00 | $0.00 |
| Scent | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Taste | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Total | $0.00 | $64.00M | $0.00 | $0.00 | $1.15B | $0.00 | $0.00 | $0.00 |
Food Ingredients, Health & Biosciences, Nourish, Pharma Solutions, Scent, Taste were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.